THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT
PUBLICATION IN APPLICATION OF ARTICLE 15 OF THE BELGIAN TRANSPARENCY ACT OF 2 MAY 2007
Acacia Pharma Group plc
Admission to Trading on Euronext Brussels
Cambridge, UK and Indianapolis, US – 23 February 2021, 08:00 CET: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that, further to the announcements on 18 February 2021 and 19 February 2021 regarding a placing of new ordinary shares in the Company (the “New Ordinary Shares“) by means of an accelerated bookbuild offering (the “Placing”), 10,000,000 New Ordinary Shares have been issued and admitted to trading on the regulated market of Euronext Brussels.
The New Ordinary Shares issued pursuant to the Placing have the same rights and benefits as, and rank pari passu in all respects with, the existing Ordinary Shares.
Following issuance of the New Ordinary Shares, as per 23 February 2021, the Company’s total issued share capital amounts to £1,993,789.02, represented by 99,689,451 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in treasury and has not issued any other voting securities. Therefore, the total number of voting rights in the Company is 99,689,451. This number represents the denominator for purposes of notifications under transparency regulations.
On the basis of this information, shareholders of the Company can verify whether they are above or below one of the thresholds of 5%, 10%, 15%, 20% and so on, in multiples of five, of the total voting rights, and whether there is therefore an obligation to disclose that they have reached, exceeded or fallen below any such threshold in accordance with the Belgian Transparency Act of 2 May 2007. Notifications of major shareholdings must be sent by email to Acacia Pharma, for the attention of Ali Elsley at AliElsley@acaciapharma.com, as well as to the Belgian Financial Services and Markets Authority (FSMA), at firstname.lastname@example.org.
The Company has in total 2,437,960 outstanding options and 2,861,500 Restricted Stock Units, for the benefit of current and former staff and the managers of the group, conferring entitlement to subscribe for a maximum total of 5,299,460 new ordinary shares, each conferring one voting right.
|Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
Mark Swallow, Frazer Hall, David Dible
Citigate Dewe Rogerson
+44 20 7638 9571
Media in Belgium and the Netherlands
Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma’s first product, BARHEMSYS® (amisulpride injection) is marketed in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centered in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.
These materials are not for release, publication or distribution, directly or indirectly, in whole or in part, into or within the United States (including its territories and possessions, any State of the United States and the District of Columbia). These materials are for informational purposes only and do not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act“), or under the securities laws of any state or other jurisdiction of the United States. The securities referred to herein may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There will be no public offer of securities in the United States.
This press release (and the information contained herein) is not for release, publication or distribution, directly or indirectly, in whole or in part, into or within Australia, Canada, Japan or South Africa or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.
The offer set out in this press release is only addressed to and is only directed at persons in member states of the European Economic Area (the “EEA“) who are “qualified investors” within the meaning of Article 2 (e) of Regulation (EU) 2017/1129. In the United Kingdom, this press release is addressed solely to, and is directed solely at, persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order“) or (ii) are persons falling within Article 49(2)(a) to (e) of the Order and other persons to whom it may lawfully be communicated (all such persons together being referred to as “relevant persons“). These materials are addressed only to, and directed only at, relevant persons and qualified investors and must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons or (ii) in any member state of the EEA, by persons who are not qualified investors. Any investment or investment activity to which these materials relate is available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire any securities referred to herein will be engaged in only with, in the United Kingdom, relevant persons, and in any member state of the EEA, qualified investors.
This press release does not constitute, or form part of, any offer or any solicitation of an offer to subscribe for any shares or other securities.